273 articles
Tenecteplase
Tenecteplase (TNKase, Metalyse) is a modified recombinant tissue plasminogen activator thrombolytic, approved in 2000 for STEMI, given as a single bolus, with 14-fold higher fibrin specificity than alteplase.
Tertatolol
Tertatolol (S 2395, Artex) is a Servier-developed nonselective beta-blocker without intrinsic sympathomimetic activity, ATC C07AA16, dosed 5 mg once daily for hypertension, with renal vasodilating and 5-HT1A antagonist properties; French marketing ended 2023.
Terutroban
Terutroban (S 18886, Triplion) is Servier's oral, reversible thromboxane-prostaglandin (TP) receptor antagonist antiplatelet drug; development stopped after the 19,120-patient PERFORM trial failed noninferiority versus aspirin.
Tetradecyl sulfuric acid
Tetradecyl sulfuric acid, as sodium tetradecyl sulfate (STS, Sotradecol), is a detergent sclerosant introduced by Leopold Reiner in 1946, FDA approved for varicose veins, used in liquid or foam sclerotherapy and compared with polidocanol.
Tezosentan
Tezosentan (Ro 61-0612) is an intravenous, short-acting dual endothelin ETA/ETB receptor antagonist developed by Actelion as a vasodilator for acute heart failure; RITZ and VERITAS trials showed hemodynamic effects but no clinical benefit, and development was discontinued.
Thiazide
Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide) block the sodium-chloride cotransporter in the distal convoluted tubule; first-line hypertension drugs since chlorothiazide's 1958 launch, also used for kidney stones and edema.
Ticrynafen
Ticrynafen (tienilic acid, Selacryn, SKF 62698) is a withdrawn uricosuric diuretic antihypertensive approved in the US in 1979, distinguished by lowering serum uric acid, and withdrawn January 1980 for immunoallergic hepatitis linked to anti-LKM2 antibodies against CYP2C9.
Tinzaparin sodium
Tinzaparin sodium (Innohep) is a porcine low-molecular-weight heparin made by heparinase depolymerization, mean MW about 6,500 Da, dosed 175 anti-Xa IU/kg once daily for DVT, PE, cancer-associated VTE, and hemodialysis circuits; FDA approved 2000.
Tocainide
Tocainide (Tonocard) is an orally active class IB antiarrhythmic lidocaine analog, FDA-approved 1984 for ventricular arrhythmias, later discontinued in the US; also trialed for neuropathic pain.
Tonapofylline
Tonapofylline (BG-9928) is a xanthine adenosine A1 receptor antagonist developed by Biogen Idec for heart failure and kidney disease; trialed in TRIDENT-1 and POSEIDON but abandoned for lack of efficacy.
Torsemide
Torsemide (torasemide), a loop diuretic approved in the US in 1993, inhibits Na+/K+/2Cl− in the loop of Henle to treat edema from heart failure, renal, or hepatic disease and hypertension; roughly twice as potent as furosemide, but TRANSFORM-HF showed no outcome difference.
Treprostinil
Treprostinil is a stable prostacyclin analogue for pulmonary arterial hypertension and PH-ILD, given orally, subcutaneously, intravenously, or inhaled; first FDA-approved 2002 (Remodulin), with Yutrepia inhalation powder approved May 2025.
Trichlormethiazide
Trichlormethiazide (Naqua, Metahydrin) is an oral thiazide diuretic similar to hydrochlorothiazide, C8H8Cl3N3O4S2, ATC C03AA06, dosed 2–4 mg daily for edema and hypertension; first approved 1960, discontinued in the US.
Triflusal
Triflusal, marketed as Disgren, is an oral antiplatelet drug related to the salicylates, used to prevent recurrent stroke and myocardial infarction in Europe and South Korea.
Triple antithrombotic therapy
Triple antithrombotic therapy, or triple therapy, combines an oral anticoagulant with aspirin and a P2Y12 inhibitor like clopidogrel after coronary stenting, most often for atrial fibrillation.
Troxerutin
Troxerutin (vitamin P4), a semi-synthetic hydroxyethylated rutin derivative, ATC C05CA04, is a capillary-stabilizing bioflavonoid used for chronic venous insufficiency, with antioxidant and venotonic effects.
Ularitide
Ularitide (urodilatin, ESP-305) is a synthetic 32-amino-acid A-type natriuretic peptide, a kidney-derived vasodilator and natriuretic drug tested in the phase III TRUE-AHF trial for acute decompensated heart failure, which showed physiological effects but no mortality benefit.
Up-titration
Up-titration is a dosing strategy in which a drug's dose is increased step by step toward a target dose proven in trials or the highest tolerated dose.
Urapidil
Urapidil (Ebrantil, B 66256) is a piperazine antihypertensive combining peripheral alpha-1 adrenoceptor blockade with central 5-HT1A agonism, used in Europe and Asia for hypertension and hypertensive emergencies; not marketed in the United States.
Valsartan
Valsartan (Diovan) is an angiotensin II receptor blocker approved in 1996 for hypertension, heart failure, and post-myocardial infarction care; also a component of sacubitril/valsartan (Entresto) and subject of 2018 nitrosamine impurity recalls.
Vasodilator therapy
Vasodilator therapy is the use of drugs that relax blood vessel muscle to widen vessels, lowering blood pressure and the heart's workload in hypertension, angina, and heart failure.
Veliflapon
Veliflapon (BAY X 1005, DG-031) is an investigational quinoline-based FLAP (ALOX5AP) inhibitor developed by Bayer for asthma and repurposed by deCODE for cardiovascular prevention; phase 3 trial suspended, never approved.
Verapamil
Verapamil is a phenylalkylamine calcium channel blocker introduced in 1962 and FDA-approved in the US in 1981, used for hypertension, angina, arrhythmias, and cluster headache prevention, with emerging beta-cell-protective roles in diabetes.
Vericiguat
Vericiguat (Verquvo; BAY-1021189, MK-1242) is an oral soluble guanylate cyclase stimulator approved in 2021 to reduce cardiovascular death and heart failure hospitalization in adults with worsening chronic HFrEF, based on the VICTORIA trial.
Vernakalant
Vernakalant (Brinavess) is an atrial-selective intravenous antiarrhythmic for rapid cardioversion of recent-onset atrial fibrillation, approved in the EU (2010) and Canada but not the US; blocks I_Kur, I_K,ACh, and rate-dependent atrial Na+ channels.
Vincamine
Vincamine, an indole alkaloid from Vinca minor (lesser periwinkle), C21H26N2O3, ATC C04AX07; cerebral vasodilator used for cerebrovascular disorders since 1959 and precursor of vinpocetine.
Vorapaxar
Vorapaxar (Zontivity, SCH 530348) is a first-in-class oral PAR-1 thrombin receptor antagonist antiplatelet drug, FDA approved in 2014 to reduce thrombotic cardiovascular events after MI or PAD, with a 173-269 h half-life and bleeding risk.
Vortosiran
RBD4059 (vortosiran) is a GalNAc-conjugated siRNA from Suzhou Ribo Life Science that silences hepatic coagulation factor XI; first-in-human trials showed durable >90% FXI suppression with 3-6 month dosing.
Xanthinol
Xanthinol (xanthinol nicotinate, xanthinol niacinate; CAS 2530-97-4 free base, 437-74-1 salt) is a water-soluble niacin-derivative vasodilator used for peripheral vascular insufficiency, causing flushing, gastric discomfort, and hypotension.
Ximelagatran
Ximelagatran (Exanta, Exarta) was AstraZeneca's oral prodrug of melagatran, the first oral direct thrombin inhibitor; noninferior to warfarin but withdrawn worldwide in February 2006 for hepatotoxicity.